Literature DB >> 12894234

Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53.

Julia V Kichina1, Sikha Rauth, Tapas K Das Gupta, Andrei V Gudkov.   

Abstract

Malignant melanomas are frequently characterized by elevated levels of wild-type p53, suggesting that p53 function could be suppressed by a mechanism different from p53 mutation. We analysed the functionality of the p53-signaling pathway in a panel of seven human melanoma cell lines consisting of one p53-deficient line, two lines with mutant p53, and four lines expressing wild-type p53. Only lines with wild-type p53 were characterized by elevated levels of endogenous p21, high activity of p53-responsive reporters and accumulation of p53 in response to genotoxic stress, common properties of functional p53. The presence of wild-type p53 was associated with depletion or loss of p14ARF and p16 expression. The levels of p33ING1b and p24ING1c, two major products of Ing1 locus and putative coregulators of p53, were elevated in all cell lines tested; however, ectopic expression of either ING1 isoform had no effect on cell proliferation. All lines retained expression of Apaf-1, and all but one remained sensitive to ectopic expression of retrovirus-transduced p53. Our data indicate that regardless of abnormally high levels of p53 in melanomas, their p53 remains competent in transactivation of its targets, and, if highly overexpressed, capable of growth inhibition. Hence, the p53 pathway in malignant melanomas can be considered for pharmacological targeting and anticancer gene therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12894234     DOI: 10.1038/sj.onc.1206741

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Ubiquitin proteasomal pathway mediated degradation of p53 in melanoma.

Authors:  Adil Anwar; David A Norris; Mayumi Fujita
Journal:  Arch Biochem Biophys       Date:  2010-12-15       Impact factor: 4.013

2.  [Isolation of mitochondrial DNA binding proteins which are specific for maize cox1 promoter].

Authors:  V I Tarasenko; I Iu Subota; V F Kobzev; Iu M Konstantinov
Journal:  Mol Biol (Mosk)       Date:  2005 May-Jun

3.  Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells.

Authors:  Tao Lu; Lyudmila G Burdelya; Shannon M Swiatkowski; Alexander D Boiko; Philip H Howe; George R Stark; Andrei V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

4.  P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation.

Authors:  Kelly A Avery-Kiejda; Nikola A Bowden; Amanda J Croft; Lyndee L Scurr; Carla F Kairupan; Katie A Ashton; Bente A Talseth-Palmer; Helen Rizos; Xu D Zhang; Rodney J Scott; Peter Hersey
Journal:  BMC Cancer       Date:  2011-05-27       Impact factor: 4.430

5.  Lebein, a Snake Venom Disintegrin, Induces Apoptosis in Human Melanoma Cells.

Authors:  Manel B Hammouda; María F Montenegro; Luis Sánchez-Del-Campo; Ons Zakraoui; Zohra Aloui; Ichrak Riahi-Chebbi; Habib Karoui; José Neptuno Rodríguez-López; Khadija Essafi-Benkhadir
Journal:  Toxins (Basel)       Date:  2016-07-05       Impact factor: 4.546

6.  Antineoplastic Effects of Honokiol on Melanoma.

Authors:  Ruth Guillermo-Lagae; Sreevidya Santha; Milton Thomas; Emily Zoelle; Jonathan Stevens; Radhey S Kaushik; Chandradhar Dwivedi
Journal:  Biomed Res Int       Date:  2017-01-17       Impact factor: 3.411

7.  p28, a first in class peptide inhibitor of cop1 binding to p53.

Authors:  T Yamada; K Christov; A Shilkaitis; L Bratescu; A Green; S Santini; A R Bizzarri; S Cannistraro; T K D Gupta; C W Beattie
Journal:  Br J Cancer       Date:  2013-06-04       Impact factor: 7.640

8.  Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax.

Authors:  Marc Mansour; Bill Pohajdak; W Martin Kast; Antar Fuentes-Ortega; Ella Korets-Smith; Genevieve M Weir; Robert G Brown; Pirouz Daftarian
Journal:  J Transl Med       Date:  2007-04-23       Impact factor: 5.531

9.  A nanotechnological, molecular-modeling, and immunological approach to study the interaction of the anti-tumorigenic peptide p28 with the p53 family of proteins.

Authors:  Emilia Coppari; Tohru Yamada; Anna Rita Bizzarri; Craig W Beattie; Salvatore Cannistraro
Journal:  Int J Nanomedicine       Date:  2014-04-10

10.  Dominant effects of Δ40p53 on p53 function and melanoma cell fate.

Authors:  Rie Takahashi; Svetomir N Markovic; Heidi J Scrable
Journal:  J Invest Dermatol       Date:  2013-09-13       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.